Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 6.25
+0.13 (2.12%)
Feb 3, 2026, 4:00 PM EST
SHA:688373 Revenue
Shanghai MicuRx Pharmaceutical had revenue of 37.02M CNY in the quarter ending September 30, 2025, with 0.52% growth. This brings the company's revenue in the last twelve months to 136.70M, up 13.85% year-over-year. In the year 2024, Shanghai MicuRx Pharmaceutical had annual revenue of 130.27M with 43.51% growth.
Revenue (ttm)
136.70M
Revenue Growth
+13.85%
P/S Ratio
30.05
Revenue / Employee
727.10K
Employees
177
Market Cap
4.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.27M | 39.50M | 43.51% |
| Dec 31, 2023 | 90.78M | 42.57M | 88.31% |
| Dec 31, 2022 | 48.21M | 40.55M | 529.33% |
| Dec 31, 2021 | 7.66M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Nanjing Well Pharmaceutical Group | 1.31B |
| Huaren Pharmaceutical | 1.26B |
| Shaanxi Panlong Pharmaceutical Group Limited By Share | 1.10B |
| Harbin Medisan Pharmaceutical | 874.60M |
| Zhejiang Shengda Bio-Pharm | 839.82M |
| Shandong Wohua Pharmaceutical | 816.95M |
| Qianjiang Yongan Pharmaceutical | 797.25M |